Expanded Haploidentical Natural Killer Cells as Consolidation Strategy for Children/Young Adults With AML
Recruiting
Phase 1
Phase 2
Interventional Study
Acute Myeloid Leukemia
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 6 Months – 21
- Sex
- Any
- Trial phase
- Phase 1/2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 15 (estimated)
- Sponsor
- Belarusian Research Center for Pediatric Oncology, Hematology and Immunology · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this study is to estimate the efficacy of immunotherapy with ex vivo expanded haploidentical NK cells as consolidation therapy for children/young adults with intermediate risk AML.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
Patients:
* primary intermediate risk AML in molecular complete remission;
* primary high risk AML in molecular complete remission awaiting unrelated HSCT;
* Karnofsky or Lansky performance scale greater or equal to 70;
* written informed consent.
Donors:
* haploidentical fam…
Contacts